☰

Demetrius Matassov, Ph.D. - Publications

Affiliations: 
2005 City University of New York, New York, NY, United States 
Area:
Cell Biology, Microbiology Biology
Tree Info Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Woolsey C, Borisevich V, Agans KN, O'Toole R, Fenton KA, Harrison MB, Prasad AN, Deer DJ, Gerardi C, Morrison N, Cross RW, Eldridge JH, Matassov D, Geisbert TW. A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus. The Journal of Infectious Diseases. PMID 37171813 DOI: 10.1093/infdis/jiad157  0.365
2022 Woolsey C, Cross RW, Agans KN, Borisevich V, Deer DJ, Geisbert JB, Gerardi C, Latham TE, Fenton KA, Egan MA, Eldridge JH, Geisbert TW, Matassov D. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. Plos Neglected Tropical Diseases. 16: e0010433. PMID 35622847 DOI: 10.1371/journal.pntd.0010433  0.338
2020 Woolsey C, Jankeel A, Matassov D, Geisbert JB, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Latham TE, Gerardi CS, Mire CE, Eldridge JH, Messaoudi I, Geisbert TW. Immune correlates of postexposure vaccine protection against Marburg virus. Scientific Reports. 10: 3071. PMID 32080323 DOI: 10.1038/S41598-020-59976-3  0.383
2020 Clarke DK, Xu R, Matassov D, Latham TE, Ota-Setlik A, Gerardi CS, Luckay A, Witko SE, Hermida L, Higgins T, Tremblay M, Sciotto-Brown S, Chen T, Egan MA, Rusnak JM, et al. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. The Lancet. Infectious Diseases. PMID 31952923 DOI: 10.1016/S1473-3099(19)30614-0  0.353
2019 Cross RW, Xu R, Matassov D, Hamm S, Latham TE, Gerardi CS, Nowak RM, Geisbert JB, Ota-Setlik A, Agans KN, Luckay A, Witko SE, Soukieh L, Deer DJ, Mire CE, et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. The Journal of Clinical Investigation. PMID 31820871 DOI: 10.1172/Jci131958  0.393
2018 Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Eldridge JH, Mire CE, Geisbert TW. Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. The Journal of Infectious Diseases. PMID 29939296 DOI: 10.1093/Infdis/Jiy293  0.377
2017 Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, Rudge TL, Sabourin CL, Egan MA, Clarke DK, Geisbert TW, et al. Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. Journal of Virology. PMID 29142131 DOI: 10.1128/Jvi.01190-17  0.339
2017 Nasar F, Matassov D, Seymour RL, Latham T, Gorchakov RV, Nowak RM, Leal G, Hamm S, Eldridge JH, Tesh RB, Clarke DK, Weaver SC. Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single dose protection against lethal alphavirus challenge. Journal of Virology. PMID 28148802 DOI: 10.1128/Jvi.01729-16  0.359
2015 Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. The Journal of Infectious Diseases. 212: S443-51. PMID 26109675 DOI: 10.1093/Infdis/Jiv316  0.401
2015 Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, Eldridge JH, Geisbert TW. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 520: 688-91. PMID 25853476 DOI: 10.1038/Nature14428  0.355
2014 Datan E, Shirazian A, Benjamin S, Matassov D, Tinari A, Malorni W, Lockshin RA, Garcia-Sastre A, Zakeri Z. MTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection Virology. 452: 175-190. PMID 24606695 DOI: 10.1016/J.Virol.2014.01.008  0.597
2009 McLean JE, Datan E, Matassov D, Zakeri ZF. Lack of Bax prevents influenza A virus-induced apoptosis and causes diminished viral replication. Journal of Virology. 83: 8233-46. PMID 19494020 DOI: 10.1128/Jvi.02672-08  0.596
2007 Matassov D, Cupo A, Galarza JM. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunology. 20: 441-52. PMID 17931114 DOI: 10.1089/vim.2007.0027  0.35
2004 Matassov D, Kagan T, Leblanc J, Sikorska M, Zakeri Z. Measurement of apoptosis by DNA fragmentation. Methods in Molecular Biology (Clifton, N.J.). 282: 1-17. PMID 15105553 DOI: 10.1385/1-59259-812-9:001  0.47
1998 García-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T. Influenza A virus lacking the NS1 gene replicates in interferon- deficient systems Virology. 252: 324-330. PMID 9878611 DOI: 10.1006/Viro.1998.9508  0.405
Show low-probability matches.